TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02810873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Mammography
Description: Undergo PEM Positron Emission Mammography scan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET Positron Emission Tomography scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo Fludeoxyglucose F-18 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo Fludeoxyglucose F-18 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper Cu 64 TP3805
Description: Undergo copper Cu 64 TP3805 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper Cu 64 TP3805
Description: Undergo copper Cu 64 TP3805 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan
Study: NCT04482764

Intervention type: DRUG
Group type: OTHER
Intervention: Valproic Acid
Description: Treatment of children with frequent cyanotic breath holding spells (at least 4 spells per week) with 5 mg/kg/day for 6 months.
Study: NCT03134248

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dailies Aquacomfort Plus Toric
Description: daily disposable contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1-Day Acuvue Moist for Astigmatism
Description: daily disposable contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyDay Toric
Description: daily disposable contact lens
Study: NCT00402077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramlintide acetate
Description: subcutaneous injection, three times a day, 120mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramlintide acetate
Description: subcutaneous injection, three times a day, 120mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramlintide acetate
Description: subcutaneous injection, three times a day, 120mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sibutramine
Description: oral tablet, once a day, 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phentermine
Description: oral tablet, once a day, 37.5mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection, three times a day
Study: NCT03606343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching Academic Skills to Kids
Description: Group treatment
Study: NCT01910493

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS reminders
Description: Intervention participants only will be sent text messages to their phones. The content of text messages will have a maximum of 160 characters and not mention HIV and will state the dates for the forthcoming consultations, visits to the pharmacy, lab results, time to take medication and reminders for patients who miss appointments.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS reminders
Description: Intervention participants only will be sent text messages to their phones. The content of text messages will have a maximum of 160 characters and not mention HIV and will state the dates for the forthcoming consultations, visits to the pharmacy, lab results, time to take medication and reminders for patients who miss appointments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS reminders
Description: Intervention participants only will be sent text messages to their phones. The content of text messages will have a maximum of 160 characters and not mention HIV and will state the dates for the forthcoming consultations, visits to the pharmacy, lab results, time to take medication and reminders for patients who miss appointments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS reminders
Description: Intervention participants only will be sent text messages to their phones. The content of text messages will have a maximum of 160 characters and not mention HIV and will state the dates for the forthcoming consultations, visits to the pharmacy, lab results, time to take medication and reminders for patients who miss appointments.
Study: NCT00991393

Intervention type: DEVICE
Intervention: INFUSE® Bone Graft
Description: Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS in the area of the dental implant on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments 6 months after surgery for placement of the appropriate prosthetic, and assessment of osseointegration and stability. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
Study: NCT03683264

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound diagnosis of avulsion of the levator ani muscle
Description: In the multi-view ultrasound images, complete avulsion was defined as an abnormal insertion of LAM in the lower pubic branch identified in all three central slices, i.e. in the plane of minimal hiatal dimensions (PMD) and the 2.5 and 5.0mm slices cranial to this one. Levator hiatus measurements, transverse diameters, anteroposterior diameters and area were also determined in the same plane (PMD).

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound diagnosis of avulsion of the levator ani muscle
Description: In the multi-view ultrasound images, complete avulsion was defined as an abnormal insertion of LAM in the lower pubic branch identified in all three central slices, i.e. in the plane of minimal hiatal dimensions (PMD) and the 2.5 and 5.0mm slices cranial to this one. Levator hiatus measurements, transverse diameters, anteroposterior diameters and area were also determined in the same plane (PMD).
Study: NCT03226782

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Short intervention protocol
Description: Will be offered an instructional material that will consist of a routine of 12 exercises to be performed autonomously for range of motion and muscular fitness, using the environmental resources of the home. It will be suggested a daily frequency in the execution of this exercise routine. Also, stimuli and guidelines will be given for the practice of active movement (walking) so that they accumulate at least 10 to 20 minutes of this activity daily. All control and training guidelines for using the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Long intervention protocol
Description: This Manual guides its implementation in a progressive way and at the end it totals about 30 to 45 min of physical exercises per day. All control and training guidelines for use of the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises. Therefore, it guides the implementation of daily walks with cumulative effect.
Study: NCT04794595

Intervention type: PROCEDURE
Intervention: CBP
Description: continuous blood purification can prevent or treat fluid overload in children with septic shock or other sepsis-associated organ dysfunction who are unresponsive to fluid restriction and diuretic therapy management of septic AKI patients, particularly those with hemodynamic instability or fluid overload. Also, it can remove cytokines
Study: NCT01612988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOMP
Description: Day-8 OMB prephase:~Ofatumumab 300 mg IV day -8 Methylprednisolone 100 mg TD IV day -8~BOMP cycle 1 and 2 :~Ofatumumab 1000 mg IV day 1 and day 15 Bendamustine 70mg IV day 2 and ady 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3 Methylprednisolone 100 mg TD IV day 15~BOMP cycle 3 to 6 :~Ofatumumab 1000 mg IV day 1 Bendamustine 70mg IV day 2 and day 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3
Study: NCT01795404

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inquiry Based Stress Reduction (IBSR)
Study: NCT01932515

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: A revised screening instrument for use in Deaf children
Study: NCT00337727

Intervention type: DRUG
Group type: OTHER
Intervention: aprepitant
Description: aprepitant 125 mg capsule; aprepitant 80 mg capsule Three day treatment period.

Intervention type: DRUG
Group type: OTHER
Intervention: Comparator: ondansetron
Description: Ondansetron 8 mg capsule Three day treatment period.
Study: NCT04084353

Intervention type: OTHER
Intervention: Intrapartum fetal monitoring training and quality improvement project
Description: Intrapartum fetal monitoring training
Study: NCT00799617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AndroGel® (testosterone gel)
Description: Testosterone levels will be measured at regular intervals in order to achieve a testosterone level in the desired range.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Testosterone levels will be measured at regular intervals.
Study: NCT03365284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Kneebrace with a smart phone app
Description: Smart Kneebrace will be used during the rehabilitation. Patients wearing the Smart KneeBrace are able to know their daily activity summary and exercise performance during rehabilitation training through a smart phone app.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: regular rehabilitation procedure
Description: regular rehabilitation procedure, especially muscle strengthening exercises
Study: NCT03545607

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MultiStem
Description: single intravenous infusion 18-36 hours after stroke

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single intravenous infusion 18-36 hours after stroke
Study: NCT03837795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback treatment
Description: A treatment that developed to train adults with sensory modulation disorder by applying EEG (Curry 7 EEG system, Neuroscan-Compumedics). This treatment will aim to normalize the Alpha power (amplitude).
Study: NCT03413332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-Talkcare
Description: Women in the intervention group will receive the E-Talkcare web address, a user name, and a temporary password. The participant will be able to read or listen (through audio narration) to instructions on how to complete the intervention in order, though she can freely navigate between web modules. Each module will have an ever-present indicator (showing users' progress) and a link to for users to continue navigating through modules.We will ask participants to complete the full intervention within 3 months after intervention delivery and then complete a 3-month post-randomization interview (T1). The website will remain open for six months after intervention delivery to allow participants to use QPL if they wish. A 6-month post-randomization interview (T2) will then be administered.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Survivors randomized to the usual care group will receive care from their doctors as usual, allowing us to compare the intervention against real-world practice to inform next steps. Since we do not know if the intervention will be efficacious, we decided not to provide a delayed intervention to control participants.
Study: NCT02143570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin
Description: Darifenacin will be prescribed in a starting dose of 7.5mg, once daily. This dose may be increased to 15mg a day in cases with refractory symptoms.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: All patients will received a tailored pelvic floor exercise programme as part of the standard of care of overactive bladder at the study centre. This intervention will be mainly comprised of biofeedback stimulation techniques.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: All patients will received a tailored pelvic floor exercise programme as part of the standard of care of overactive bladder at the study centre. This intervention will be mainly comprised of biofeedback stimulation techniques.
Study: NCT00676442

Intervention type: DRUG
Group type: OTHER
Intervention: PN400
Description: naproxen/esomeprazole

Intervention type: DRUG
Group type: OTHER
Intervention: PN400
Description: naproxen/esomeprazole

Intervention type: DRUG
Group type: OTHER
Intervention: PN400
Description: naproxen/esomeprazole

Intervention type: DRUG
Group type: OTHER
Intervention: PN400
Description: naproxen/esomeprazole
Study: NCT03955042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 900 mg/m\^2 on Day 1 of each 21-day cycle. Supportive medications of ibuprofen, folic acid, vitamin B12, and dexamethasone.
Study: NCT01513252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gröber and Buschke test
Description: spontaneous delayed recall score after a 5 years follow-up
Study: NCT00337727

Intervention type: DRUG
Group type: OTHER
Intervention: Comparator: ondansetron
Description: Ondansetron 8 mg capsule Three day treatment period.

Intervention type: DRUG
Group type: OTHER
Intervention: Comparator: dexamethasone
Description: dexamethasone 12 mg tablets; 20 mg tablets Three day treatment period.

Intervention type: DRUG
Group type: OTHER
Intervention: Comparator: dexamethasone
Description: dexamethasone 12 mg tablets; 20 mg tablets Three day treatment period.

Intervention type: DRUG
Group type: OTHER
Intervention: Comparator: fosaprepitant dimeglumine
Description: fosaprepitant dimeglumine 115 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Comparator; Placebo (unspecified)
Description: dexamethasone 12mg Pbo tablets.
Study: NCT03940378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamisole Hydrochloride
Description: Levamisole Hydrochloride Levamisole Hydrochloride 25mg/tablet; 150mg/d; po;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsules
Description: Anlotinib Hydrochloride Capsules Anlotinib Hydrochloride Capsules 12mg / capsule; 12mg/d; po;
Study: NCT00337727

Intervention type: DRUG
Group type: OTHER
Intervention: Comparator; Placebo (unspecified)
Description: Aprepitant 80 mg \& 125 mg Pbo capsules.
Study: NCT03444909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cardiotocograph
Description: Monitoring of 20 min with the cardiotocograph

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cardiotocograph
Description: Monitoring of 20 min with the cardiotocograph
Study: NCT03940378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsules
Description: Anlotinib Hydrochloride Capsules Anlotinib Hydrochloride Capsules 12mg / capsule; 12mg/d; po;
Study: NCT03632291

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-221
Description: UB-221 (75 mg/ml)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-221
Description: UB-221 (75 mg/ml)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-221
Description: UB-221 (75 mg/ml)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-221
Description: UB-221 (75 mg/ml)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-221
Description: UB-221 (75 mg/ml)
Study: NCT03061539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab & Ipilimumab
Description: Combination Therapy: Cohort 1: Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks for a maximum of 4 cycles . Cohort 2 : Nivolumab 3mg/kg + ipilimumab 1mg/kg every 3 weeks for a maximum of 4 cycles.~Treatment free gap after last combination dose : Cohort 1: 6 weeks; Cohort 2: 3 weeks~Monotherapy: 480 mg flat dose of nivolumab every 4 weeks for up to 10 cycles, or until progression, unacceptable toxicity or withdrawal of consent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab & Ipilimumab
Description: Combination Therapy: Cohort 1: Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks for a maximum of 4 cycles . Cohort 2 : Nivolumab 3mg/kg + ipilimumab 1mg/kg every 3 weeks for a maximum of 4 cycles.~Treatment free gap after last combination dose : Cohort 1: 6 weeks; Cohort 2: 3 weeks~Monotherapy: 480 mg flat dose of nivolumab every 4 weeks for up to 10 cycles, or until progression, unacceptable toxicity or withdrawal of consent
Study: NCT01516879

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection once a month

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection once a month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Background lipid lowering therapy: 10 mg or 80 mg atorvastatin orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Background lipid lowering therapy: 10 mg or 80 mg atorvastatin orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Background lipid lowering therapy: ezetimibe 10 mg orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ezetimibe
Description: Background lipid lowering therapy: ezetimibe 10 mg orally once a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Only
Description: Diet only, no lipid lowering background drug given

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diet Only
Description: Diet only, no lipid lowering background drug given
Study: NCT01072201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triclosan and Fluoride
Description: Brush twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Brush twice daily
Study: NCT00647621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Phenytoin Sodium Capsules 100 mg
Description: 3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dilantin® Kapseals® 100 mg
Description: 3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
Study: NCT03641352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 0.5mg
Description: CKD-501 0.5mg, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759. CKD-501 placebo will be changed to CKD-501 from extension study to EOS(end of study).
Study: NCT03989193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer guided alveolar ridge splitting technique
Description: The bone splitting technique could be performed using the piezoelectric system, calibrating the device on D1 setting and using profuse saline irrigation. The preparation sequence begins with CS3 insert until a total depth of 10mm was achieved across the entire extension of the ridge. The procedure continued with the CS1 insert and finally the CS2 insert.~The vertical bone cuts through the cortical layer: At the distal end of the horizontal split, a vertical cut will made with the high-speed bur within the vicinity of the buccal plate to start the separation, with a full vertical depth of 13 mm. Final design of the splitting cut was L-shaped split. At the distal and the mesial end of the horizontal split, a vertical cut was made with the high-speed bur for a full vertical depth of 13mm.
Study: NCT04295603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toucher Massage (TM) on the feet
Description: The intervention for the Experimental Group (EG) includes a massage time of about 15 minutes (according to current Geneva Hospital practice) on the foot area. At least four sessions will be delivered and spread over two weeks. The TM will be provided by the care team. The training time for the workers corresponds to 2 times 2 hours. In order to be as close as possible to a standardized session, practitioners will benefit from an intervention guide.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homedics HM MP RELEX 90 device
Description: The Control Group (CG) will benefit from an intervention of identical duration. The treatment consists of a foot massage with a Homedics HM MP RELEX 90 device, a heat-free shiatsu program, which lasts about 15 minutes. The use of the Homedics device is no more a common treatment than the practice of Touch-Massage. TM involves a therapeutic relationship between caregiver and patient. It is for this reason that we need a comparator that should allow us to keep the aspect of the massage while decreasing the aspect of the therapeutic relationship and therefore offer us an adequate comparator.
Study: NCT00584038

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: educational instruction and phone follow-up
Description: Educational instruction and phone follow-up.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: educational instruction in clinic
Description: Educational instruction in clinic.
Study: NCT00220025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: The patient begins total body NBUVB that day at a dose that is 50% of the MED. Patients are treated 3-7 times per week, with increasing doses at every treatment if no burning occurs. This is continued until clearance of disease or maximum efficacy.
Study: NCT00678561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Topical treatment once daily for 28 days
Study: NCT03444909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cardiotocograph
Description: Monitoring of 20 min with the cardiotocograph

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toconaute
Description: Monitoring of 20 min withToconaute

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toconaute
Description: Monitoring of 20 min withToconaute